Cell therapy approaches to autism: a review of clinical trial data.
Jack PricePublished in: Molecular autism (2020)
A number of clinical trials of cell therapies for autism spectrum disorder have been conducted, and some have published their outcomes. This review considers the data that have emerged from this small set of published trials, evaluates their success, and proposes further steps that could be taken if this field of endeavour is to be pursued further. A number of reservations arise from this tranche of studies, specifically the absence of identified therapeutic targets, and deficiencies in the therapeutic approach that is being employed. If this therapeutic direction is to be pursued further, then additional pre-clinical studies are recommended that might lead to improvements in patient stratification, biomarkers, the defined mode of action, and the preparation and identification of the therapeutic cells themselves.
Keyphrases
- cell therapy
- clinical trial
- autism spectrum disorder
- electronic health record
- intellectual disability
- stem cells
- induced apoptosis
- mesenchymal stem cells
- phase ii
- big data
- single cell
- attention deficit hyperactivity disorder
- metabolic syndrome
- open label
- type diabetes
- machine learning
- mass spectrometry
- double blind
- study protocol
- working memory
- endoplasmic reticulum stress
- cell proliferation
- signaling pathway
- meta analyses
- deep learning
- molecularly imprinted
- high resolution
- skeletal muscle